Koen Andries

Janssen (Belgium) — Belgium

Medicine · Health Sciences

71h-index20.2kcitations193works4.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(66), HIV/AIDS drug development and treatment(45), HIV Research and Treatment(44), Mycobacterium research and diagnosis(38), Viral Infections and Immunology Research(30)

Publications192 total

Sub-MIC levels of bedaquiline and clofazimine can select <i>Mycobacterium tuberculosis</i> mutants with increased MIC
Antimicrobial Agents and Chemotherapy·2024· 4 citedOpen Access
Minimal effective dose of bedaquiline administered orally and activity of a long acting formulation of bedaquiline in the murine model of leprosy
PLoS neglected tropical diseases·2023· 7 citedOpen Access
Bedaquiline- and clofazimine- selected Mycobacterium tuberculosis mutants: further insights on resistance driven largely by Rv0678
Scientific Reports·2023· 23 citedOpen Access
Minimal effective dose of oral bedaquiline and activity of a long acting formulation of bedaquiline in the murine model of leprosy Bedaquiline for the treatment of leprosy
2023Open Access
Impact of <i>Rv0678</i> mutations on patients with drug-resistant TB treated with bedaquiline
The International Journal of Tuberculosis and Lung Disease·2022· 14 citedOpen Access
Efficacy of Long-Acting Bedaquiline Regimens in a Mouse Model of Tuberculosis Preventive Therapy
American Journal of Respiratory and Critical Care Medicine·2021· 16 cited
Fully weekly antituberculosis regimen: a proof-of-concept study
European Respiratory Journal·2020· 4 citedOpen Access
Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection
Antimicrobial Agents and Chemotherapy·2019· 42 citedOpen Access
Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection
2019· 6 citedOpen Access
Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial
PLoS ONE·2018· 18 citedOpen Access
Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units
Bioorganic & Medicinal Chemistry Letters·2017· 57 citedOpen Access
6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis
ACS Medicinal Chemistry Letters·2017· 79 citedOpen Access
In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria
Journal of Medical Microbiology·2017· 58 citedOpen Access
Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline
The International Journal of Tuberculosis and Lung Disease·2016· 4 cited
Unexpected high prevalence of resistance-associated<i>Rv0678</i>variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline
Journal of Antimicrobial Chemotherapy·2016· 169 citedOpen Access
Cytochrome bd as survival factor in mycobacteria
Biochimica et Biophysica Acta (BBA) - Bioenergetics·2016Open Access
In vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against M. tuberculosis
Médecine et Maladies Infectieuses·2016· 26 cited
Mutations in <i>pepQ</i> Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis
Antimicrobial Agents and Chemotherapy·2016· 208 citedOpen Access
Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in <i>Mycobacterium tuberculosis</i> Infected C3HeB/FeJ Mice
ACS Infectious Diseases·2016· 152 citedOpen Access
Bedaquiline (R207910 or TMC207), a new candidate for the treatment of multidrug resistant tuberculosis
2016
page 1 of 10Next →

Frequent Co-authors

Rudi Pauwels(14), Jérôme Guillemont(11), Nacer Lounis(11), Anil Koul(11), Paul A. J. Janssen(10), Eddy Arnold(9), Kalyan Das(8), Michael J. Kukla(7), Dirk Bald(7), Jan Heeres(6), Marc R. de Jonge(6), Stephen H. Hughes(5), Paul Lewi(5), Lucien M. H. Koymans(5), Marie‐Pierre de Béthune(5), Eric L. Nuermberger(5), Vincent Jarlier(4), Alexander S. Pym(4), Tine De Marez(4), Paul Meyvisch(4)